ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1455	National Cancer Institute	Html	en	Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Merkel cell carcinoma.	inadequate surgical margins 0.329956 cell polyomavirus infection. 0.336356 lymph node dissection 0.348903 Australian Merkel cell 0.385562 Distinct merkel cell 0.383584 neuroendocrine) carcinoma. 0.357189 node-positive Merkel cell 0.37626 Cell Carcinoma Information 0.370356 Ann Surg Oncol 0.393202 Rockville Merkel Cell 0.387174 clinical trials 0.331337 distant metastatic disease 0.331199 newly diagnosed patients 0.336848 cell carcinoma tumors 0.386769 Merkel cell cancer 0.385012 metastatic disease 0.334729 advanced merkel cell 0.38315 patients 0.398223 human Merkel cell 0.391488 Merkel cell polyoma 0.396025 lymph node biopsy 0.394484 sentinel lymph node 0.424128 Merkel tumours 0.360064 Merkel cell carcinomas 0.385298 primary Merkel cell 0.398409	et al. 0.396589 wide local excision 0.340871 case series 0.379017 Arch Dermatol 0.332282 cutaneous Merkel-cell carcinoma 0.356835 PUBMED Abstract 0.359039 adjuvant radiation therapy 0.370608 Invest Dermatol 0.331034 neuroendocrine-merkel cell carcinoma 0.369705 MCC patients 0.350161 Surg Oncol 0.397083 merkel cell carcinoma 0.931809 Abstract 0.399239 Clin Oncol 0.38708 cell polyomavirus sequences 0.331565 Dermatol Surg 0.33595 Carcinoma Group 0.350591 cell carcinoma demographics 0.372267 Trabecular carcinoma 0.351339 cell polyomavirus DNA 0.331118 lymph node 0.427173 cell carcinoma adjuvant 0.368757 merkel cell polyomavirus 0.477468 lymph node metastases 0.330714	CLICK HERE
1538	National Cancer Institute	Html	en	Coenzyme Q10 (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of coenzyme Q10 as a treatment for people with cancer.	cell respiration 0.339879 naturally occurring forms 0.338495 new blood cells 0.340323 United States 0.340183 plasma coenzyme 0.469789 clinical examination 0.347068 cell growth 0.340428 animal immune systems 0.339418 cancer cells 0.357416 above-mentioned human studies 0.339569 follow-up study 0.36193 quinone chemical group 0.341067 breast cancer prognosis. 0.348287 cellular energy production 0.369553 cancer therapy 0.341253 free radical damage 0.357523 dietary supplements 0.352656 blood levels 0.35773 IND application process 0.337121 anthracycline anticancer drug 0.341617 cancer information summary 0.355992 coenzyme q10 0.913438 free radicals 0.338619 anthracycline drug doxorubicin 0.340494	high-dose coenzyme 0.460691 uncontrolled clinical study 0.342321 clinical drug research 0.340343 specific disease prevention 0.33723 breast cancer patients 0.409089 adjuvant therapy 0.341472 animal studies 0.378869 Investigational New Drug 0.337296 important cellular components 0.338608 normal blood levels 0.341607 protective effect 0.341278 radiation therapy 0.379802 high-level coenzyme 0.453918 aerobic energy production 0.337109 Low blood levels 0.340721 indirect anticancer activity 0.337514 lung cancer cells 0.348538 single-dose radiation therapy 0.3393 standard therapy 0.337625 coenzyme Q10. 0.469116 benzoquinone compound 0.3465 follow-up study report 0.341395 original study 0.33952	CLICK HERE
1576	National Cancer Institute	Html	en	Prostate Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for prostate cancer.	PDQ Screening 0.238955 prostate gland 0.262783 following PDQ summaries 0.255959 Cancer Information Service 0.234967 PDQ cancer information 0.447798 Prevention Editorial Board 0.248763 men 0.210517 National Cancer Institute 0.335949 clinical trials 0.389256 PDQ documents 0.200757 test result 0.223183 benign prostatic hyperplasia 0.273839 cancer information summary 0.326548 newly diagnosed prostate 0.284247 clinical trial 0.213023 new treatment 0.208327 breast cancer prevention 0.217981 early cancer detection 0.236129	Cancer screening trials 0.28054 test 0.242059 Cancer Care page 0.221557 PDQ database 0.205174 prostate cancer gene 0.339499 NCI’s PDQ 0.209119 prostate cancer screening 0.411947 PDQ summary 0.286479 cancer symptoms 0.211597 NCI PDQ cancer 0.287762 prostate cancer 0.971006 tests 0.264624 bigger prostate 0.262229 PSA test 0.20487 Prostate Cancer Prevention 0.350483 cancer information summaries 0.242796 comprehensive cancer information 0.243032 high PSA level 0.200418	CLICK HERE
1580	National Cancer Institute	Html	en	Skin Cancer Screening (PDQ®)–Patient Version	Having a skin exam to screen for skin cancer has not been shown to decrease your chance of dying from skin cancer. Learn about this and other tests that have been studied to detect or screen for skin cancer in this expert reviewed summary.	PDQ Screening 0.323371 skin cancer 0.833312 cancer treatment 0.285886 cancer screening methods 0.360926 United States 0.282138 ongoing clinical trials 0.355632 screening tests 0.287638 cancer cells 0.293854 following PDQ summaries 0.338661 Cancer Information Service 0.328048 PDQ cancer information 0.497713 squamous cells 0.320712 squamous cell skin 0.32842 white men 0.281879 Prevention Editorial Board 0.34433 treatment clinical trials 0.288708 National Cancer Institute 0.431189 clinical trials 0.547197 PDQ documents 0.289835 inner layer 0.288892 test result 0.316842 cancer information summary 0.417477 melanoma skin cancer 0.385616 new treatment 0.294602	breast cancer prevention 0.311531 skin cancer screening 0.419518 Cancer screening trials 0.367401 NCI website 0.290521 Regular skin checks 0.306952 Cancer Care page 0.315809 PDQ database 0.293213 latest published information 0.29227 risk factor 0.309102 NCI’s PDQ 0.299274 PDQ summary 0.314752 UV radiation 0.308073 cancer symptoms 0.303698 doctor 0.289249 NCI PDQ cancer 0.373425 tests 0.320045 cancer information summaries 0.334989 nonmelanoma skin cancer 0.420432 comprehensive cancer information 0.335151 basal cell carcinoma 0.354359 cancer 0.95489 basal cells 0.2875 squamous cell carcinoma 0.357881	CLICK HERE
1766	National Cancer Institute	Html	en	Accidents at Nuclear Power Plants and Cancer Risk	A fact sheet about cancer risks associated with accidents at nuclear power plants.	Atomic Radiation 0.316376 Radiation risks 0.325562 radiation exposures 0.328269 nuclear accident sites 0.293301 Radiation Research 0.323015 low levels 0.272065 nuclear power plant 0.97677 I-131 exposure 0.297263 radiation sickness 0.405841 high doses 0.352667 radiation emergencies 0.31438 Chernobyl nuclear power 0.302487 Additional radioactive isotopes 0.311741 dangerous radioactive isotopes 0.306851 cancer patients 0.299868 greatest cancer risks 0.294897 cancer risks 0.312758 radioactive materials 0.379547 radiation therapy 0.335122 unstable isotopes 0.274 Radiation Effects Research 0.350011 external radiation 0.312725 power plant disaster 0.278559 radioactive isotopes 0.53284 ionizing radiation 0.412892	health effects 0.355744 future nuclear accidents 0.300229 nuclear reactors 0.284713 power plant accident 0.397996 nuclear weapons explosions 0.282249 thyroid gland 0.292634 thyroid cancer 0.388789 radiation exposure 0.375545 power plant accidents 0.566854 Radiation Emergency Medical 0.344768 I-131 0.306486 radioactive exposure 0.273465 National Cancer Institute 0.340697 specific radioactive materials 0.295979 breast cancer risk 0.282358 Radiation Epidemiology Branch 0.341242 Chernobyl-related thyroid cancer 0.291023 radiation 0.697647 cancer risk 0.309268 et al 0.275755 medical x-ray machines 0.33168 cancer 0.423405 Chernobyl accident 0.42803 certain radioactive isotopes 0.3079	CLICK HERE
1863	National Cancer Institute	Html	es	Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas.	cell leukemia treated 0.413444 cell leukemia patients 0.427269 long-term follow-up 0.427434 Rituximab with pentostatin 0.40359 Peaud PY 0.40245 hairy cell leukaemia 0.411122 initially with pentostatin 0.406363 Foucar MK 0.403895 leukemia patients treated 0.417121 leukemia following treatment 0.406508 células pilosas 0.473847 treated with rituximab 0.403745 Instituto Nacional 0.402568 cell leukemia following 0.408562 Else M 0.404329 with pentostatin 0.442439 or refractory hairy 0.403457 VH4-34+ hairy cell 0.404297 Natl Cancer Inst 0.402731 Federico M 0.402782 Leuk Lymphoma 0.424893 long term 0.40908 patients treated with 0.423309 Burian C 0.403658 Matutes E 0.403796	leukemia treated with 0.41301 patients with hairy 0.610395 following treatment with 0.408927 Italian Cooperative Group 0.40697 hairy-cell leukemia with 0.408245 relapsed or refractory 0.403586 National Cancer Institute 0.404377 after treatment with 0.408757 untreated patients with 0.407444 with poor prognosis 0.40323 with 2-CdA 0.403201 cell leukemia with 0.426877 treatment with 0.420376 hairy cell leukemia 0.998262 Clin Oncol 0.444146 treated with pentostatin 0.422653 leukemia with pentostatin 0.404444 leukemia after treatment 0.406381 Long term results 0.402405 treated with 0.429875 treated initially with 0.406289 previously untreated patients 0.40321 PDQ Sofocos 0.402915 cell leukemia after 0.412869	CLICK HERE
2048	National Cancer Institute	Html	es	Pruebas de Papanicolaou y del virus del papiloma humano (VPH)	Hoja informativa que describe los exámenes selectivos de detección del cáncer de cérvix, los cuales incluyen la prueba de Papanicolaou y la prueba de los virus del papiloma humano.	Lancet Oncology 0.30494 alta probabilidad 0.305241 Clinical Pathology 0.316699 siguientes categorías 0.313238 undergoing concurrent testing 0.307924 American Society 0.338185 Schiffman M 0.323335 pruebas conjuntas 0.308272 Sociedad Estadounidense 0.311719 Task Force Recommendation 0.307945 Preventive Services Task 0.350595 Cervical Pathology 0.322689 low-grade squamous 0.308742 Roche Molecular Systems 0.307924 Estados Unidos 0.346024 cervical cancer 0.362845 Clinical Pathology screening 0.309437 cobas hpv test 0.3092 PubMed Abstract 0.387591 categoría cin-2 0.304985 categoría cin-3 0.305133 human papillomavirus 0.356046 Cancer Journal 0.30689 atypical squamous cells 0.360558 Sistema Bethesda 0.324914	Patología Cervical 0.309863 lesiones asc-h 0.305566 categorías cin-2 0.305175 United States Preventive 0.309063 cuidado médico 0.306651 lesiones asc-us 0.30675 Katki HA 0.31204 alto riesgo 0.931083 clinical practice 0.304727 Drug Administration 0.304664 cervical cytology 0.30862 Servicios Preventivos 0.304816 Wacholder S 0.311753 resultado asc-us 0.312665 papillomavirus testing 0.305257 HPV cotesting 0.306351 resultados benignos 0.305213 Services Task Force 0.349973 cervical intraepithelial neoplasia 0.314986 mejores resultados 0.304652 Cancer Institute 0.314518 graves anomalías 0.316853 infecciones pasajeras 0.309673 squamous cell carcinoma 0.313148	CLICK HERE
2067	National Cancer Institute	Html	es	Terapia hormonal para el cáncer de seno	Hoja informativa que describe la terapia hormonal y su función en la prevención y tratamiento del cáncer de seno. Incluye información acerca de los efectos secundarios posibles y de los fármacos que pueden interferir con la terapia hormonal.	Surgical Adjuvant Breast 0.34336 Lancet Oncology 0.360626 Sestak I 0.320955 seno her2 y HR 0.354769 endocrine-responsive early breast 0.32332 endocrine therapy 0.324855 Preventing breast 0.319374 advanced breast 0.370204 Adjuvant hormonal therapy 0.333366 Cuzick J 0.320795 Vogel VG 0.310952 as adjuvant treatment 0.327521 efectos agonistas 0.311137 combined survival analysis 0.309596 Pippen J 0.31114 randomized trial comparing 0.312309 Collaborative Group 0.311107 seno hr 0.420398 hormonal therapy 0.348519 PubMed Abstract 0.906244 Surgical Oncology Clinics 0.312057 Clinical Oncology 0.330375 with advanced breast 0.322297 prior endocrine therapy 0.310537 early breast cancer 0.522236	alto riesgo 0.314676 hormonas estrógeno 0.407972 Bowel Project 0.309666 Wickerham DL 0.323539 aromatasa anastrozol 0.350666 initial adjuvant therapy 0.311523 Breast Cancer Group 0.336508 Costantino JP 0.33801 P-2 Trial 0.309919 Bowel Project Study 0.309651 seno er 0.390638 developing invasive breast 0.321634 standard hormonal therapy 0.329685 adjuvant endocrine therapy 0.312843 Italian Tamoxifen Anastrozole 0.312927 breast cancer 0.858969 Breast Cancer Trialists 0.369705 IBIS-I breast 0.319452 Forbes JF 0.31136 enzima llamada 0.312883 tamoxifen treatment 0.320843 Cancer Institute 0.344896 seno her2 0.38128 primary breast 0.320324	CLICK HERE
15584	National Cancer Institute	Html	en	Childhood Cancer Genomics (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genomics of childhood cancer. The summary describes the molecular subtypes for specific pediatric cancers and their associated clinical characteristics, the recurring genomic alterations that characterize each subtype at diagnosis or relapse, and the therapeutic and prognostic significance of the genomic alterations. The genomic alterations associated with brain tumors, kidney tumors, leukemias, lymphomas, sarcomas, and other cancers are discussed.	childhood cancers 0.451916 genomic landscape 0.448565 leukemia cell lines 0.468388 Leukemia Group study 0.460885 Pediatric Acute Myeloid 0.449186 B-cell precursor 0.478228 childhood B-cell precursor 0.465086 B-acute lymphoblastic leukemia 0.506359 poor prognosis 0.440387 mutations 0.5002 children 0.490055 acute lymphoblastic leukaemia 0.700198 specific mutations 0.439289 AML 0.440256 Childhood Acute Lymphoblastic 0.50969 acute lymphoblastic leukemias 0.496998 chromosomal abnormalities 0.446518 CEBPA mutations 0.439533 oncology group study 0.489092 leukemia development 0.4551 B-precursor Acute Lymphoblastic 0.495043 patients 0.462491 prognostic significance 0.476271 Nat Genet 0.458917 Hyperdiploid leukemia cells 0.465322	childhood cancer 0.441528 et al. 0.603959 lymphoblastic leukemia interacts 0.498545 high-risk acute 0.4447 pre-B cell leukemia 0.456422 Pediatr Blood Cancer 0.444419 acute myeloid leukemia 0.542492 Moorman AV 0.468863 acute lymphocytic leukemia 0.496126 acute lymphoblastic leukaemias 0.511116 favorable prognosis 0.439188 point mutations 0.44293 B-acute lymphoblastic leukaemia 0.466866 cases 0.445244 genomic alterations 0.438134 Abstract 0.573806 Clin Oncol 0.509945 favorable outcome 0.455497 blood 0.45817 Acute promyelocytic leukemia 0.495963 pathogenic germline mutations 0.450974 acute lymphoblastic leukemia 0.983229 acute leukemia 0.50127 Mullighan CG 0.471025	CLICK HERE
17171	National Cancer Institute	Html	es	PC-SPES (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	médico herborista 0.418438 Centro Nacional 0.430037 New Hampshire Avenue 0.420405 Drug Administration 0.412734 NCI Best Case 0.437012 datos bibliográficos pubmed 0.422243 siguientes preguntas 0.413766 demostró efectos 0.424258 siguientes riesgos 0.417668 seguro médico 0.412292 múltiples problemas 0.418438 Instituto Nacional 0.517971 acupuntura ayuda 0.412243 Salud Complementaria 0.450225 Visuals Online 0.415643	complementarias revisa 0.422417 Physician Data Query 0.491682 Estados Unidos 0.863449 actúa pc-spes 0.442835 libre uso 0.415953 suficiente cantidad 0.41905 página manejo 0.414584 ¿El tratamiento 0.421322 Nueva York 0.418373 ¿Los beneficios 0.413162 siguientes medicamentos 0.438285 Series Program 0.413051 medicina complementaria 0.925538 diferentes lotes 0.423892	CLICK HERE